beyond spring pharma stock

BYSI stock price quote stock graph news analysis. The company or beyondspring nasdaq.

Stock Overview Beyondspring

BeyondSpring is a noticeably small company with a market capitalisation of US392m.

. The Company or BeyondSpring NASDAQ. The stock hit its 52-week high of 33 on Aug. Joining us on todays call is Dr.

Shares of BeyondSpring BYSI 985 soared on Wednesday after the pharmaceutical company released promising clinical trial results for its investigational lung cancer treatment. Our collaborations research and support are leading to exciting new discoveries and an amplified sense of hope for patients. 30 2021 GLOBE NEWSWIRE BeyondSpring Inc.

BeyondSpring GAAP EPS of -164 beats by 002 revenue of 135M misses by 722M Seeking Alpha 32d BeyondSpring Q4 2021 Earnings Preview Seeking Alpha 32d BeyondSpring is about to announce. BYSI Q4 2021 Earnings Call Transcript. The combination met the primary endpoint of increasing overall survival and met key secondary endpoints BeyondSpring New York said.

Find real-time BYSI - Beyondspring Inc stock quotes company profile news and forecasts from CNN Business. This is managed by Dr Asok Dutta BVScAH and Dr Udaya Kumar Maiya MD Oncologist. Our lead asset a first-in-class agent plinabulin is a selective immunomodulating microtubule-binding agent that is being.

The service offers end-to-end research on both investing and trading ideas everyday and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked. 4D pharma has a consensus target price of 4000 suggesting. BeyondSpring presently has a consensus target price of 3000 suggesting a potential upside of 217273.

According to the issued ratings of 6 analysts in the last year the consensus rating for BeyondSpring stock is Hold based on the current 1 sell rating 3 hold ratings and 2 buy ratings for BYSI. Bysi a global biopharmaceutical company focused on the development of. 4D pharma has a consensus target price of 4000 suggesting a potential upside of.

BYSI Complete BeyondSpring Inc. Dr Dutta is. BYSI stock was up 154 as of Wednesday afternoon.

Lan Huang Beyond Springs co-founder chairman and chief executive officer. Beyond spring pharma stock Monday February 21 2022 Edit. NEW YORK Dec.

On the date of publication Nick Clarkson did not have either directly or indirectly any. The stock recently traded at 2711 compared with its. Discover historical prices for BYSI stock on Yahoo Finance.

The Companyâs lead product Plinabulin which is being studied as an. This suggests a possible upside of. View real-time stock prices and stock quotes for a full financial overview.

The average twelve-month price target for BeyondSpring is 3000 with a high price target of 6500 and a low price target of 500. BeyondSpring Inc a clinical stage biopharmaceutical company together with its subsidiaries focuses on the development and commercialization of immuno-oncology cancer. The current BeyondSpring BYSI share price is 132.

The service offers end-to-end research on both investing and trading ideas everyday and includes a 150-stock. Czerepak has over 30 years of experience in big pharma biotechnology and venture capital. The Company is focused on developing cancer therapies to improve clinical outcomes for patients who have high unmet medical needs.

The latest closing stock price for BeyondSpring as of May 17 2022 is 127. The stock recently traded at 2711 compared with its Tuesday close at 963. By the close of.

Engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. Clinical stage biopharma companies BeyondSpring BYSI and CTI BioPharma CTIC have gained 49 and 45 in the pre-market respectively on below-average volume as investors await. New york april 08 2022 globe newswire -- beyondspring inc.

Is a clinical-stage global biopharmaceutical company. TOGETHER WERE MAKING A DIFFERENCE IN CANCER TREATMENT The treatment landscape is changing almost daily and were at the forefront with our innovative immuno-oncology cancer therapies and robust pipeline. BYSI a global biopharmaceutical company focused on the development of innovative cancer therapies today announced its financial results for the third quarter ended September 30 2021 and provided an update on recent corporate events.

Real time BeyondSpring Inc. Headquartered in New York City we are committed to raising the standard of care for cancer patients with first-in-class treatments that improve lives and clinical outcomes for millions of patients in need.

Circling Back On Beyondspring Bysi Stock Seeking Alpha

Beyondspring Linkedin

Beyondspring Analyst Sees Little Trouble In Big China Nasdaq

Circling Back On Beyondspring Bysi Stock Seeking Alpha

Beyondspring Stock Lack Of Transparency Creates Downside Risk Nasdaq Bysi Seeking Alpha

Pipeline Beyondspring

Beyondspring Pharmaceuticals Announces New Positive Data On Plinabulin From Its Chemotherapy Induced Neutropenia Prevention Program At The European Society For Medical Oncology 2021 Congress